Evidence map›Paper›PMID 32188494›Full record

ArticleArthritis research & therapy2020

Lipocalin 2 links inflammation and ankylosis in the clinical overlap of inflammatory bowel disease (IBD) and ankylosing spondylitis (AS).

Aifeng Lin, Robert D Inman, Catherine J Streutker, Zhenbo Zhang, Kenneth P H Pritzker, Hing Wo Tsui, Florence W L Tsui

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arthritis research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Aifeng LinInstitute of Medical Science, University of Toronto, Toronto, Ontario, Canada. fernaifenglin@gmail.com.
Robert D InmanInstitute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
Catherine J StreutkerDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Zhenbo ZhangKrembil Research Institute, University Health Network, Toronto, Ontario, Canada.
Kenneth P H PritzkerKeyIntel Medical Inc, Toronto, Ontario, Canada.
Hing Wo TsuiKrembil Research Institute, University Health Network, Toronto, Ontario, Canada.
Florence W L TsuiKeyIntel Medical Inc, Toronto, Ontario, Canada.
University of Toronto · CAKrembil Research InstituteTrudell Medical International (Canada) · CA

Funding

Canadian Institute of Health Research
6 · The paper itself

Abstract

backgroundLittle is known about the mechanisms underlying the clinical overlap between gut inflammation and joint ankylosis, as exemplified by the concurrence of inflammatory bowel diseases (IBD) and ankylosing spondylitis (AS). As dysbiosis may serve as a common contributor, the anti-microbial pleiotropic factor lipocalin 2 could be a potential mediator due to its roles in inflammation and bone homeostasis.

methodsBaseline colonic pathology was conducted in the ank/ank mouse model. Serum lipocalin 2 was analyzed by ELISA, in ank/ank mutants versus C3FeB6-A/A

resultsThis study showed that the ank/ank mice with fully fused spines had concurrent colonic inflammation. By first using the ank/ank mouse model with progressive ankylosis and subclinical colonic inflammation, confirmed in patients with concurrent AS and IBD, elevated circulating lipocalin 2 levels were associated with the coexisting ankylosis and gut inflammation. The intracellular pathway of lipocalin 2 was further investigated with the ank/ank mouse model involving PPARγ. Colonic expression of PPARγ was negatively associated with the degree of gut inflammation. The PPARγ agonist rosiglitazone treatment significantly upregulated the serum levels of lipocalin 2, suggesting a potential regulatory role of PPARγ in the aberrant expression of lipocalin 2.

conclusionsIn summary, lipocalin 2 modulated by PPARγ could be a potential pathway involved in concurrent inflammation and ankylosis in AS and IBD.

Indexed as

Disease Models, AnimalAnimalsAnkylosisFemaleHumansInflammationInflammatory Bowel DiseasesLipocalin-2MaleMice, KnockoutPPAR gammaRosiglitazoneSpondylitis, AnkylosingUp-RegulationLipocalin-2PPAR gammaRosiglitazoneank/ank miceAnkylosing spondylitisInflammatory bowel diseasesLipocalin 2PPARγ

Identifiers

PMID32188494
PMCPMC7081573
OpenAlexW3011992646

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.